| Identification | Back Directory | [Name]
{2-[(4-{[Bis-(2-tert-butoxycarbonylamino-ethyl)-amino]-methyl}-benzyl)-(2-tert-butoxycarbonylamino-ethyl)-amino]-ethyl}-carbamic acid tert-butyl ester | [CAS]
1807521-06-7 | [Synonyms]
Ph-Bis(C1-N-(C2-NH-Boc)2)
{2-[(4-{[Bis-(2-tert-butoxycarbonylamino-ethyl)-amino]-methyl}-benzyl)-(2-tert-butoxycarbonylamino-ethyl)-amino]-ethyl}-carbamic acid tert-butyl ester
tert-Butyl N-(2-{[(4-{[bis(2-{[(tert-butoxy)carbonyl]amino}ethyl)amino]methyl}phenyl)methyl](2-{[(tert-butoxy)carbonyl]amino}ethyl)amino}ethyl)carbamate | [Molecular Formula]
C36H64N6O8 | [MDL Number]
MFCD28142457 | [MOL File]
1807521-06-7.mol | [Molecular Weight]
708.929 |
| Hazard Information | Back Directory | [Biological Activity]
Ph-Bis(C1-N-(C2-NH-Boc)2) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | [References]
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
|
|